Published in Health Business Week, October 15th, 2004
The company also issued these investors warrants to purchase an aggregate of 10,685,730 shares of its common stock at an exercise price of $0.42 per share, which if exercised would provide Biopure with additional proceeds of approximately $4.5 million.
Under Biopure's current operating plan the company believes that its cash on hand should fund operations through January 2005. The company intends to aggressively manage its expenses...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.